REZOLUTE, INC. Cash and Restricted Cash
REZOLUTE, INC. (RZLT) had Cash and Restricted Cash of $10.62 million as of 2026-06-30, per its 10-K filed 2026-09-24.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-09-24
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10.62M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $11.24M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $11.94M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $9.10M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $10.62M 10-K · filed 2026-09-24 | |
| 2026-03-31 | $11.24M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $11.94M 10-Q · filed 2026-02-12 | |
| 2025-09-30 | $9.10M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $94.11M 10-K · filed 2026-09-24 | |
| 2025-03-31 | $14.60M 10-Q · filed 2026-05-12 | |
| 2024-12-31 | $8.93M 10-Q · filed 2026-02-12 | |
| 2024-09-30 | $10.47M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $70.40M 10-K · filed 2026-09-24 | |
| 2024-03-31 | $5.93M 10-Q · filed 2025-05-13 | |
| 2023-12-31 | $12.50M 10-Q · filed 2025-02-12 | |
| 2023-09-30 | $8.06M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $16.04M 10-K · filed 2025-09-17 | |
| 2023-03-31 | $33.74M 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $146.75M 10-Q · filed 2024-02-13 | |
| 2022-09-30 | $154.32M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $150.41M 10-K · filed 2024-09-19 | |
| 2022-03-31 | $68.42M 10-Q · filed 2023-05-11 | |
| 2021-12-31 | $82.40M 10-Q · filed 2023-02-10 | |
| 2021-09-30 | $37.29M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $41.05M 10-K · filed 2023-09-14 | |
| 2021-03-31 | $31.99M 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $37.60M 10-Q · filed 2022-02-09 | |
| 2020-09-30 | $6.40M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $9.96M 10-K · filed 2022-09-15 | |
| 2020-03-31 | $14.03M 10-Q · filed 2021-05-17 | |
| 2019-12-31 | $19.71M 10-Q · filed 2021-02-10 | |
| 2019-09-30 | $25.21M 10-Q · filed 2020-11-12 | |
| 2019-08-31 | $14.00M 10-Q · filed 2020-05-14 | $19.70M 10-Q · filed 2020-02-12 |
| 2019-06-30 | $11.57M 10-K · filed 2021-09-15 | |
| 2019-03-31 | $15.34M 10-Q · filed 2020-05-14 | |
| 2018-12-31 | $258.00K 10-Q · filed 2020-02-12 | |
| 2018-09-30 | $401.00K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $11.57M 10-K · filed 2021-09-15 | $1.65M 10-K · filed 2019-09-10 |
| 2017-06-30 | $4.49M 10-K · filed 2019-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |